Cadonilimab, a PD-1/CTLA-4 bi-specific antibody, is being developed by Akeso, Inc. for the treatment of a range of solid tumors, including cervical cancer, lung cancer, gastric/gas
- Study number:
- NCT06140589
- Cohorts:
- 1
- Study phase:
- N/A
- Overall status:
- Recruiting
- Study type:
- Any